Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

EMA Recommends Granting a Marketing Authorisation for the Hybrid Medicine Chlormethine

It is intended for the treatment of mycosis fungoides-type cutaneous T-cell lymphoma
22 Dec 2016
Haematologic malignancies;  Anticancer agents & Biologic therapy

On 15 December 2016, the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending granting a marketing authorisation for the medicinal product chlormethine (Ledaga), intended for the treatment of mycosis fungoides-type cutaneous T-cell lymphoma.

Ledaga was designated as an orphan medicinal product on 22 May 2012.

The applicant for this medicinal product is Actelion Registration Ltd.

Ledaga will be available as a 160 μg/g gel. The active substance of Ledage is the antineoplastic chlormethine (ATC code: L01AA05), a bifunctional alkylating agent that inhibits rapidly proliferating cells.

The benefits with Ledaga are its ability to treat cutaneous T cell lymphoma lesions leading to resolution of skin patches, plaques and tumours.

The most common side effects are related to skin adverse reactions such as dermatitis, pruritis, skin infections, skin ulceration and blistering, and skin hyperpigmentation.

Ledaga is a hybrid medicine of Caryolysine which has been authorised in the EU since 1946. Ledaga contains the same active substance as Caryolysine, but will be available as a gel for cutaneous use.

Studies have demonstrated the satisfactory quality of Ledaga. Since Ledaga is administered as a topical agent resulting in no systemic exposure, a bioequivalence study versus the reference product Caryolysine was not required. Hybrid applications rely in part on the results of pre-clinical tests and clinical trials for a reference product and in part on new data.

The full indication is: "Ledaga is indicated for the topical treatment of mycosis fungoides-type cutaneous T-cell lymphoma (MF-type CTCL) in adult patients."

Detailed recommendations for the use of this product will be described in the summary of product characteristics, which will be published in the European public assessment report and made available in all official European Union languages after the marketing authorisation has been granted by the European Commission.

Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 days from adoption of the opinion.  

Last update: 21 Dec 2016

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.